TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21663717

Group type: EXPERIMENTAL
Intervention: Preoperative interscalene block with 30 mL of 0.5% ropivacaine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo with 10 mL of saline solution
Number of subjects: 53
Study: 19922568

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17998689

Group type: EXPERIMENTAL
Intervention: Arm A: XRT 30 Gy/10 fr/2 weeks + EBBT 8 Gy (2 sessions)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Arm B: XRT 30 Gy/10 fr/2 weeks + EBBT 10 Gy (1 session)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Arm C: EBBT 15 Gy (1 session) without XRT
Number of subjects: 45
Study: 12759489

Group type: EXPERIMENTAL
Intervention: Omalizumab (0.016 mg/kg/IgE every 4 weeks)
Number of subjects: 35
Study: 10970702

Group type: EXPERIMENTAL
Intervention: HRQoL instruments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Technique based on ordinal HRQoL data
Number of subjects: 0
Study: 9241285

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2000 mg/day)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 8284118

Group type: EXPERIMENTAL
Intervention: Proved EV infection
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Severe multisystem disease
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Markers of severe disease
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 57
Study: 3549507

Group type: EXPERIMENTAL
Intervention: Sclerotherapy (1% polidocanol, performed twice weekly until varices eradicated)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Propranolol (twice daily, mean dose 161 +/- 80 mg per day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 70
Study: 30028479

Group type: EXPERIMENTAL
Intervention: Proprioceptive training (gaze direction recognition exercise)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 40
Study: 26763851

Group type: EXPERIMENTAL
Intervention: Losartan potassium tablets (50‐100 mg per day)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Levamlodipine besylate tablets (2.5‐5.0 mg per day)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Both groups (Losartan and Levamlodipine)
Number of subjects: 244
Study: 25068412

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) using 40 mL ropivacaine 0.5%
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravenous fentanyl (IVFE) 1.5 μg/kg
Number of subjects: 41
Study: 22709704

Group type: EXPERIMENTAL
Intervention: Baked beetroot (200 g with ≥500 mg nitrate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cranberry relish (eucaloric placebo)
Number of subjects: 11
Study: 20977845

Group type: EXPERIMENTAL
Intervention: Lund concept
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 68
Study: 18626166

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg and Normal saline (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 60
Study: 15728536

Group type: EXPERIMENTAL
Intervention: Animal compound-free (ACF) medium
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ACF medium combined with poloxamer 188
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ACF medium after 30 days of storage and deswelling in poloxamer 188
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ACF medium alone and combined with poloxamer 188
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard commercialized media containing 2% FCS
Number of subjects: 56
Study: 12574563

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (2.5, 5, or 10 mg orally twice daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 10473306

Group type: EXPERIMENTAL
Intervention: Psychological debriefing plus education
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 157

Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 157
Study: 7573996

Group type: EXPERIMENTAL
Intervention: 5% lidocaine with dextrose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with dextrose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1.5% dextrose-free lidocaine
Number of subjects: 8
Study: 1851069

Group type: COMPARATOR
Intervention: Control (n = 6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-selective beta-adrenoceptor blockade (propranolol) (n = 6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-selective beta-adrenoceptor blockade (n = 6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cholinergic blockade (atropine) (n = 6)
Number of subjects: 24
Study: 7028085

Group type: EXPERIMENTAL
Intervention: Timolol alone followed by epinephrine after 2 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epinephrine alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Simultaneous timolol and epinephrine treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Timolol followed by epinephrine
Number of subjects: 16
Study: 31674920

Group type: EXPERIMENTAL
Intervention: Vivibot chatbot (experimental group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Daily emotion ratings (control group)
Number of subjects: 45
Study: 28765638

Group type: EXPERIMENTAL
Intervention: 3D reconstruction using laser projective point and projection invariant from five points on a 2D target
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3D reconstruction approach
Number of subjects: 0
Study: 26154926

Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate citrate (FPC) administered via dialysate (2 μmol/l of iron)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (standard dialysate)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate citrate (FPC) administered via dialysate
Number of subjects: 103
Study: 23343672

Group type: EXPERIMENTAL
Intervention: Food basket with health and nutrition education
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Food basket without health and nutrition education
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Cash with health and nutrition education
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Cash without health and nutrition education
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Food basket group (obese women)
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Cash group (obese women)
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Food basket group (BMI 25-30 kg/m2)
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Cash group (BMI 25-30 kg/m2)
Number of subjects: 3010
Study: 21084403

Group type: EXPERIMENTAL
Intervention: Intravenous insulin treatment (IIT) for 24 hours targeting glycemia less than 110 mg/dl
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard treatment (ST) with regular insulin if glycemia was greater than 200 mg/dl
Number of subjects: 70
Study: 19179971

Group type: EXPERIMENTAL
Intervention: Two-layer compression system
Number of subjects: 112

Group type: COMPARATOR
Intervention: Four-layer compression system
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Patients with simultaneous insufficiency of two venous systems (superficial and deep)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Patients with insufficiency of deep, superficial and perforating venous system
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Localization on the back calf region
Number of subjects: 112
Study: 17289894

Group type: EXPERIMENTAL
Intervention: Cetuximab 250 mg/m2 (weekly)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cetuximab (single doses of 250-500 mg/m2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cetuximab (various single doses: 50, 100, 250, 400, 500 mg/m2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cetuximab (250 mg/m2)
Number of subjects: 39
Study: 15498524

Group type: EXPERIMENTAL
Intervention: Dimethylglycine (400 mg daily for 28 days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (daily for 28 days)
Number of subjects: 7
Study: 14563654

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day orally)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10614805

Group type: EXPERIMENTAL
Intervention: Postprocedural chest pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Return to catheterization laboratory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late postprocedural pain
Number of subjects: 0
Study: 8532482

Group type: EXPERIMENTAL
Intervention: Faking Good
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Teacher
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Ideal Teacher
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control (standard directions)
Number of subjects: 384
Study: 1827102

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 120
Study: 6453571

Group type: EXPERIMENTAL
Intervention: Lumbar flexion exercise
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Home care
Number of subjects: 28
Study: 30618197

Group type: EXPERIMENTAL
Intervention: GDC-3280
Number of subjects: 0
Study: 30054895

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2000-500 mg every 8 hours
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Avibactam 2000-500 mg every 8 hours
Number of subjects: 42
Study: 26757276

Group type: EXPERIMENTAL
Intervention: Three-dose intramuscular (i.m.) artesunate regimen (4 mg/kg at 0, 24, and 48 hours)
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Three-dose intravenous (i.v.) artesunate regimen (4 mg/kg at 0, 24, and 48 hours)
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Five-dose intramuscular (i.m.) artesunate regimen (2.4 mg/kg at 0, 12, 24, 48, and 72 hours)
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Delayed anemia (post hoc analysis)
Number of subjects: 1047
Study: 24216034

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir 800/100 mg once daily monotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: darunavir/ritonavir 800/100 mg once daily + two NRTIs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whole group
Number of subjects: 30
Study: 22278424

Group type: COMPARATOR
Intervention: Cabergoline monotherapy (0.5 mg once daily for 18 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of cabergoline and pegvisomant (10 mg daily for 12 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pegvisomant (10 mg daily after cabergoline withdrawal for 12 weeks)
Number of subjects: 24
Study: 20634277

Group type: EXPERIMENTAL
Intervention: Arithmetic learning condition 1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Arithmetic learning condition 2
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Post-training improvements
Number of subjects: 70
Study: 17694391

Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette Guerin (BCG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15774238

Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing vitamin E, selenium, vitamin C, and coenzyme Q10
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12042275

Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg/day in two divided doses for 4 weeks)
Number of subjects: 313

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 313
Study: 9801994

Group type: EXPERIMENTAL
Intervention: Intralipid plus heparin (250 ml 10% Intralipid plus 5000 U heparin)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg, orally, at 0 min and at 210 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7625469

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 80 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31938726

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) using active-play video games (i.e., Xbox Kinect) and traditional cardiovascular exercise equipment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Stretching-and-toning (ST) control intervention
Number of subjects: 200
Study: 30037817

Group type: EXPERIMENTAL
Intervention: Trastuzumab-based regimen (paclitaxel plus trastuzumab with or without lapatinib)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Integrated RNA and DNA models
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Models using RNA only
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Multiplatform models including gene signatures, clinical features, and DNA information
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Somatic DNA alterations (mutation, CNAs), tumor molecular subtype (HER2E, Luminal), and microenvironment (immune cells)
Number of subjects: 137
Study: 26474861

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin–tazobactam (CI)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin–tazobactam (II)
Number of subjects: 78
Study: 24909499

Group type: EXPERIMENTAL
Intervention: Tedizolid (200 mg once daily for 6 days)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Linezolid (600 mg twice daily for 10 days)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Tedizolid
Number of subjects: 666

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 666
Study: 23140598

Group type: EXPERIMENTAL
Intervention: Posterior approach (Group 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Anterior approach (Group 2)
Number of subjects: 62
Study: 19942995

Group type: EXPERIMENTAL
Intervention: Combined continuous rachidian and peridural analgesia (CRPA)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Continuous peridural analgesia (CPA)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 128
Study: 17893311

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1162
Study: 14722206

Group type: EXPERIMENTAL
Intervention: BIIL 284 25 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BIIL 284 150 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11280672

Group type: EXPERIMENTAL
Intervention: Automode (AM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: synchronised intermittent mandatory ventilation (SIMV)
Number of subjects: 40
Study: 9459192

Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg p.o. once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg p.o. once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Letrozole (both doses combined)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Letrozole (both doses)
Number of subjects: 30
Study: 7943584

Group type: EXPERIMENTAL
Intervention: Intraoperative hepatic ultrasonography (IOUS)
Number of subjects: 62
Study: 3540835

Group type: EXPERIMENTAL
Intervention: Surfactant therapy (bovine surfactant, surfactant TA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 41
Study: 31896118

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (160 IU)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 30409109

Group type: EXPERIMENTAL
Intervention: CGRP
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 26473443

Group type: EXPERIMENTAL
Intervention: Pilates exercise program (1 hour, 2 times a week)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (continued daily activities)
Number of subjects: 47
Study: 26215666

Group type: EXPERIMENTAL
Intervention: Immediate vaccination of eligible adults with single dose vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaccination delayed by 21 days
Number of subjects: 0
Study: 23539885

Group type: EXPERIMENTAL
Intervention: Highly purified human menopausal gonadotropin (HP-hMG)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Recombinant human follicle-stimulating hormone (rhFSH)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal inserts (PVI)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Intramuscular injection of progesterone in oil (PIO)
Number of subjects: 173
Study: 21106086

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice daily
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 18808279

Group type: EXPERIMENTAL
Intervention: Hypnotized participants responding to unanswerable and misleading questions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-hypnotized participants responding to unanswerable and misleading questions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypnotized participants responding to answerable questions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-hypnotized participants responding to answerable questions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General findings regarding DK responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General findings regarding unanswerable questions
Number of subjects: 0
Study: 15986229

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg body weight Roc (Roc group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1.0 mg/kg succinylcholine (Sux; control group)
Number of subjects: 120
Study: 12552184

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg intravenous
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenous
Number of subjects: 135

Group type: COMPARATOR
Intervention: Droperidol 0.625 mg intravenous and dexamethasone 4 mg intravenous (control)
Number of subjects: 135
Study: 10540047

Group type: EXPERIMENTAL
Intervention: Dalteparin sodium 5000 units s.c. injection administered twice daily for 12 weeks
Number of subjects: 12
Study: 8911400

Group type: EXPERIMENTAL
Intervention: Thrombolysis (rt-PA)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Thrombolysis (UK)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Surgical revascularization
Number of subjects: 237
Study: 1989365

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) by mask
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (self‐administered chest physiotherapy alone)
Number of subjects: 43
Study: 6815974

Group type: EXPERIMENTAL
Intervention: Bupivacaine 50 mg (another 50 mg 4 h later)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 mg morphine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 mg morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 29589414

Group type: EXPERIMENTAL
Intervention: Mepivacaine (20 mL, 15 mg/mL) for axillary nerve block
Number of subjects: 117
Study: 29703335

Group type: EXPERIMENTAL
Intervention: GEM-P (intravenous gemcitabine 1000 mg/m2 on days 1, 8, and 15, cisplatin 100 mg/m2 on day 15, and oral or intravenous methylprednisolone 1000 mg on days 1-5) every 28 days for four cycles
Number of subjects: 87

Group type: COMPARATOR
Intervention: CHOP (intravenous cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 [maximum 2 mg] on day 1, and oral prednisolone 100 mg on days 1-5) every 21 days for six cycles
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: GEM-P
Number of subjects: 87

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 87
Study: 26540238

Group type: EXPERIMENTAL
Intervention: Mobile Telehealth (MTH) intervention
Number of subjects: 81
Study: 25440807

Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard sedation (control)
Number of subjects: 50
Study: 22229650

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol and remifentanil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inhalational anaesthesia with sevoflurane and fentanyl
Number of subjects: 50
Study: 20550223

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 626

Group type: COMPARATOR
Intervention: Temsirolimus + IFNalpha
Number of subjects: 626
Study: 18090045

Group type: EXPERIMENTAL
Intervention: Ritonavir (800 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amprenavir (1200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15054216

Group type: EXPERIMENTAL
Intervention: Gene expression profiles in peripheral blood mononuclear cells of autoimmune individuals and unaffected first‐degree relatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gene expression profiles in normal individuals after immunization
Number of subjects: 0
Study: 11697387

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment for unborn children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 9558288

Group type: EXPERIMENTAL
Intervention: IFN‐alpha2b (6 megaunits/m2 thrice weekly for 24 weeks)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 144
Study: 8092901

Group type: COMPARATOR
Intervention: H2 blocker (continuous infusion of ranitidine at 0.25 mg/kg/hr after a loading dose of 0.5 mg/kg) plus antacids
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g every 6 hours via nasogastric tube)
Number of subjects: 98
Study: 3287907

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Number of subjects: 209

Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg
Number of subjects: 209

Group type: COMPARATOR
Intervention: Aspirin 648 mg
Number of subjects: 209
Study: 4343678

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate and oxymetholone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31954417

Group type: EXPERIMENTAL
Intervention: Generating positive arguments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generating negative arguments
Number of subjects: 0